Follow us on Twitter
This page is updated frequently with new Aspirin-related patents. Subscribe to the Aspirin RSS feed to automatically get the update: related Aspirin RSS feeds.
Subscribe to updates on this page: Aspirin RSS
|| List of recent Aspirin-related patents
| Analgesic composition and method of making the same|
A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solubilizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia..
|Compounds with super-aspirin effects|
A compound having the structural formula (i) and pharmaceutically acceptable salt and/or hydrates thereof, (i) wherein y is an arylester or an c1-c8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —cl, —br, a c1-c8 alkyl, benzyl, a c1-c8 alkoxy, benzyloxy, —nhc(o)r, —nh2, —no2—ono2, —(ch2)nono2, —oc(o)[(ch2)n]cyclicono2, —ocoarono2, —ocoar(ch2)nono2 or a c1-c5 haloalkyl ester, wherein r is a c1-c8 alkyl or a c1-c8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.. .
|Aspirin derivatives and uses thereof|
The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer..
|Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin|
Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an hmg-coa reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation..
|Orally disintegrating tablet|
The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration.. .
|Resolvins: bioemplates for novel therapeutic interventions|
The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (pufa) such as eicosapentaenoic acid (epa) or docosahexaenoic acid (dha), cyclooxygenase-ii (cox-2) and an analgesic, such as aspirin (asa). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy epa or dha compounds having unique structural and physiological properties.
|Process for inhibition of cerebral damage associated with ischemia by anthocyanins and anthocyanidins|
A composition is also provided that includes ananthocyanin compound to cause blood clot dissolution. The agent being in specific embodiments is tissue plasminogen activator or aspirin..
|Blister pack for a container|
The present invention relates to a blister pack sealed to the neck of a container and adapted to fit under the container lid forming a seal, said blister pack containing a liquid soluble material such as dissolvable aspirin. When force is applied to the blister pack, the base, which is comprised of a rupturable material, breaks and allows the liquid soluble material to be mixed with the liquid in the container.
|Method and composition to improve absorption of therapeutic agents|
A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling.
Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin.
|Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof|
The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity.
The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives..
|Formulations from natural products, turmeric, paclitaxel, and aspirin|
The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.. .
Popular terms: [SEARCH]
Aspirin topics: Acetylsalicylic Acid, Cardiovascular Disease, Cardiovascular, Vascular Disease, Calcium Carbonate, Nitroglycerin, Epinephrine, Eicosapentaenoic Acid, Docosahexaenoic Acid, Polyunsaturated Fatty Acid, Fondaparinux, Bivalirudin, Paclitaxel, Salicylic Acid, Vascular Diseases
Follow us on Twitter
This listing is a sample listing of patents related to Aspirin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Aspirin with additional patents listed. Browse our RSS directory or Search for other possible listings.